«Future neoantigen vaccine trials will recruit more patients with advanced disease to test the efficacy of the vaccine, take advantage of improved methods for predicting antigen presentation to boost the number of effective neoantigens and test for synergy with checkpoint blockade and other immunotherapeutics,» the scientists said. (sciencedaily.com)
While talking about neoantigen vaccines, researchers also refer to checkpoint inhibitors: another emerging form of immunotherapy that positively stimulates the immune system in cancer patients. (cnbc.com)
Meanwhile, several biotech companies are launching trials combining neoantigen vaccines and checkpoint inhibitors for various cancers, including Neon Therapeutics in Cambridge, which Wu and Hacohen co-founded. (sciencemag.org)